In the last trading session, 1.38 million Sangamo Therapeutics Inc. (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.10. With the company’s per share price at $1.00 changed hands at $0.0 or -0.07% during last session, the market valuation stood at $177.16M. SGMO’s last price was a discount, traded about -480.0% off its 52-week high of $5.80. The share price had its 52-week low at $0.77, which suggests the last value was 23.0% up since then. When we look at Sangamo Therapeutics Inc.’s average trading volume, we note the 10-day average is 1.03 million shares, with the 3-month average coming to 1.84 million.
Analysts gave the Sangamo Therapeutics Inc. (SGMO) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.20. If we narrow down to specifics, the data shows that 0 out of 11 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 2 recommended SGMO as a Hold, 7 felt it is a Buy and 1 rated the stock as Underweight. Sangamo Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.32.
Sangamo Therapeutics Inc. (NASDAQ:SGMO) trade information
Instantly SGMO was in red as seen at the end of in last trading. With action 13.02%, the performance over the past five days has been green. The drop to weekly highs of 1.1500 on Friday, 09/15/23 subtracted -0.07% to the stock’s daily price. The company’s shares are showing year-to-date downside of -68.18%, with the 5-day performance at 13.02% in the green. However, in the 30-day time frame, Sangamo Therapeutics Inc. (NASDAQ:SGMO) is 7.90% up. Looking at the short shares, we see there were 10.46 million shares sold at short interest cover period of 8.1 days.
The consensus price target for the stock as assigned by Wall Street analysts is $6.01, meaning bulls need an upside of 83.36% from its current market value. According to analyst projections, SGMO’s forecast low is $1.50 with $10.00 as the target high. To hit the forecast high, the stock’s price needs a -900.0% plunge from its current level, while the stock would need to soar -50.0% for it to hit the projected low.
Sangamo Therapeutics Inc. (SGMO) estimates and forecasts
Data shows that the Sangamo Therapeutics Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -53.08% over the past 6 months, a 9.60% in annual growth rate that is considerably lower than the industry average of 11.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Sangamo Therapeutics Inc. will rise 5.90%, while the growth in revenue is estimated to hit 18.80% for the next quarter. Year-over-year growth is forecast to reach 65.00% up from the last financial year.
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of $9.36 million. 10 analysts are of the opinion that Sangamo Therapeutics Inc.’s revenue for the quarter ending Dec 2023 will be $8.36 million. The company’s revenue for the corresponding quarters a year ago was $26.59 million and $27.23 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -64.80%. The estimates for the next quarter sales put growth at -69.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -12.30%. The 2023 estimates are for Sangamo Therapeutics Inc. earnings to decrease by -1.00%.
Sangamo Therapeutics Inc. is expected to release its next quarterly earnings report in October.
Sangamo Therapeutics Inc. (NASDAQ:SGMO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 14.43% of Sangamo Therapeutics Inc. shares while 65.69% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.76%. There are 65.69% institutions holding the Sangamo Therapeutics Inc. stock share, with Wasatch Advisors LP the top institutional holder. As of Jun 29, 2023, the company held 9.63% of the shares, roughly 17.05 million SGMO shares worth $22.17 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 8.97% or 15.89 million shares worth $20.66 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Wasatch Ultra Growth Fund and Wasatch Small Cap Growth Fund. With 6.48 million shares estimated at $8.42 million under it, the former controlled 3.66% of total outstanding shares. On the other hand, Wasatch Small Cap Growth Fund held about 2.51% of the shares, roughly 4.44 million shares worth around $5.77 million.